At a glance
- Originator Aventis
- Class Neuroprotectants; Nootropics
- Mechanism of Action Glycine agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 22 Jan 1997 No-Development-Reported for Cognition disorders in European Union (Unknown route)